Market Exclusivity and Changes in Competition and Prices Associated With the US Food and Drug Administration Unapproved Drug Initiative.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 33999110.
- Also identified by DOI 10.1001/jamainternmed.2021.1989 and PMC identifier 8129902.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cohort study assesses the long-term associations of the US Food and Drug Administration Unapproved Drug Initiative with market exclusivity characteristics and price changes.
Medical subject headings
- Drug Approval
- Drug Industry
- Economic Competition